Bovie Medical Corporation (the “Company”) (NYSE Amex: BVX), a manufacturer and marketer of electrosurgical products, today announced that it has entered into an exclusive agreement with Medical Illumination International, Inc. San Fernando, CA to bring a new generation of medical lighting to the medical community in the United States. This line of LED lights features a 4300 degree Kelvin white light which uses half the electricity and produces a small fraction of the heating intensity of the old standard halogen lighting. The LED lights include an extended life of 50,000 hours which is approximately twenty-five times longer than halogen lighting. The agreement also includes Bovie exclusively distributing Medical Illumination’s non-LED medical lights as well as any new LED lights under development. Rob Saron, president of Bovie Medical stated, “We are excited to add this domestic manufactured line of medical lighting as a compliment to our electrosurgical products, since it represents the same call point for both our sales representatives and distribution partners.” Certain matters discussed in this news release and oral statements made from time to time by representatives of the Company may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Although the Company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions, it can give no assurance that its expectations will be achieved. Forward-looking information is subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected. Many of these factors are beyond the Company’s ability to control or predict. Important factors that may cause actual results to differ materially and that could impact the Company and the statements contained in this news release can be found in the Company’s filings with the Securities and Exchange Commission. For forward-looking statements in this new release, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise.
For further information about the Company’s current and new products, please refer to the Investor Relations section of Bovie’s website www.boviemedical.com.